RecruitingNot ApplicableNCT05713435

Use of Fractional CO2 Laser Versus Erbium:YAG Laser for the Treatment of GSM in Patients Using Aromatase Inhibitors

Use of Fractional CO2 Laser Versus Erbium:YAG Laser for the Treatment of Genitourinary Syndrome of Menopause (GSM) in Patients Using Aromatase Inhibitors: Double Blinded Randomized Controlled Clinical Trial.


Sponsor

Universitaire Ziekenhuizen KU Leuven

Enrollment

162 participants

Start Date

Dec 27, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

To study the efficacy and safety of intravaginal CO2 laser versus intravaginal Er:YAG laser and sham application in alleviating genitourinary symptoms in patients receiving an aromatase inhibitor as adjuvant treatment of breast cancer


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 100 Years

Inclusion Criteria6

  • Recruited participants will meet all of these criteria:
  • a history of breast cancer
  • premenopausal at diagnosis of breast cancer
  • using AI as an adjuvant treatment
  • moderate to severe symptoms of GSM (VAS ≥ 4/10)
  • currently menopausal, which can be either biochemical menopause as confirmed after chemotherapy, surgical or medicinally induced (GnRH analogues for the duration of the trial)

Exclusion Criteria11

  • Not willing to abstain from vaginal intercourse for 1 week following laser therapy
  • Use of non-hormonal vaginal preparations within the last 6 weeks before inclusion
  • Use of hormonal therapy within 6 months prior to inclusion (systemic or local)
  • Acute urinary or genital tract infections
  • A history of genital fistula, a thin rectovaginal septum as determined by the investigator, or history of fourth degree laceration
  • Prolapse ≥ grade 2 according to the Pelvic Organ Prolapse Quantification System
  • Previous vaginal mesh implantation
  • Abnormal result in the last cervical smear (maximum 36 month before enrollment)
  • Active cancer treatment (radiotherapy or chemotherapy) ongoing or planned prior to the measurement of the primary outcome (6 months after inclusion, 3 months after last laser)
  • Vaginal stenosis that does not allow the placement of the laser probe
  • Any condition that could interfere with study compliance

Interventions

DEVICEintravaginal laser

application of intravaginal laser


Locations(1)

UZ Leuven

Leuven, Flemish Brabant, Belgium

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05713435


Related Trials